Novolog(第二型糖尿病)市場分析與到2020年的預測

本報告已在2012年02月24日停止出版。

更改為出版

NovoLog (第二型糖尿病治療藥物):開發平台分析及市場預測

NovoLog (Type 2 Diabetes) - Analysis and Forecasts to 2020

出版日期 : 2012年01月

商品編碼: 232255

簡介

本報告提供第二型糖尿病治療藥物的Novolog調查分析，第二型糖尿病市場特徵，糖尿病的分類、 抗糖尿病治療的演變，藥物治療的相關概述，Novolog臨床研究和核准歷史記錄，銷售的影響因素，也提供藥物評估，銷售預測等，為您概述為以下內容。

第1章 目錄

第2章 簡介

• 糖尿病市場
• 免疫學
  • 得病率
  • 死亡率
• 疾病和風險因素
  • 肥胖
  • 久坐的生活方式
  • 家族病史與遺傳學
  • 人種
  • 高齡化
• 糖尿病的經濟影響
• 該報告內容架構

第3章 第二型糖尿病:市場特徵

• 第二型糖尿病市場
• 第二型糖尿病市場預測
• 第二型糖尿病市場:推動因素·阻礙因素
  • 推動因素
  • 阻礙因素

第4章 糖尿病的分類

• 糖尿病的形式
  • 第一型糖尿病
  • 第二型糖尿病
  • 妊娠性糖尿病
• 糖尿病的併發症
  • 循環系統疾病
  • 腎臟病
  • 神經病變
  • 截肢
  • 視網膜症

第5章 抗糖尿病治療的演變

第6章 藥物治療

• 胰島素
• 口服藥
  • Sulfonylureas(SUR)
  • 雙胍類(Biguanides ) (BGD)
  • Alpha-Glucosidase Inhibitors(AGI)
  • Meglitinides
  • Thiazolidinediones(TZD)
  • Dipeptidyl PeptidaseIV(DPP-IV)抑制劑
  • 口服藥的聯合治療
• 其他的注射藥物
  • Pramlintide
  • Exenatide
• 第二型糖尿病的各級的市場佔有率

第7章 Novolog(insulin aspart)

• 簡介
• 作用機制
• 臨床研究
  • 第二型糖尿病的Novolog的皮下注射治療
  • 第二型糖尿病的幫浦療法
• Novolog的核准歷史記錄
• 銷售的影響因素
  • 胰島素市場擴大
  • 正常人體胰島素(RHI)與贏過其他胰島素類似物的Novolog的優點
  • 防止兩餐之間血糖上升
  • 夜間的低血糖的有效治療
  • 開始時的競爭率非常低
• 藥物評估
  • 藥物風險效益評分
  • 競爭的激烈程度
• 銷售預測
  • 以Novolog為對象的患者群
  • 施打
  • 市場的普及
  • 年度治療費用
  • Novolog銷售預測

第8章 附錄

圖表

目錄

Summary

GlobalData's pharmaceuticals report, "NovoLog (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides NovoLog sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of NovoLog including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis ofNovoLog including efficacy, safety, pricing and other details which influence its sales potential
• Detailed sales forecast for 2011-2020 for NovoLog in the US, EU5 and Japan

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug's performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1. Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Introduction

• 2.1 Diabetes
• 2.2 Epidemiology
  • 2.2.1 Prevalence
  • 2.2.2 Mortality
• 2.3 Etiology and Risk Factors
  • 2.3.1 Obesity
  • 2.3.2 Sedentary Lifestyle
  • 2.3.3 Family History and Genetics
  • 2.3.4 Ethnicity
  • 2.3.5 Old Age
• 2.4 Economic Impact of Diabetes
• 2.5 GlobalData Report Guidance

3. Type 2 Diabetes: Market Characterization

• 3.1 Type 2 Diabetes Market
• 3.2 Type 2 Diabetes Market Forecasts
• 3.3 Type 2 Diabetes Market: Drivers and Restraints
  • 3.3.1 Drivers
  • 3.3.2 Restraints

4. Classification of Diabetes

• 4.1 Types of Diabetes
  • 4.1.1 Type 1 Diabetes
  • 4.1.2 Type 2 Diabetes
  • 4.1.3 Gestational Diabetes
• 4.2 Diabetes Complications
  • 4.2.1 Cardiovascular Disease
  • 4.2.2 Nephropathy
  • 4.2.3 Neuropathy
  • 4.2.4 Amputation
  • 4.2.5 Retinopathy

5. Evolution of Anti-Diabetic Treatments

6. Medications

• 6.1 Insulin
• 6.2 Oral Medications
  • 6.2.1 Sulfonylureas (SUR)
  • 6.2.2 Biguanides (BGDs)
  • 6.2.3 Alpha-Glucosidase Inhibitors (AGI)
  • 6.2.4 Meglitinides
  • 6.2.5 Thiazolidinediones (TZDs)
  • 6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors
  • 6.2.7 Oral Combination Therapy
• 6.3 Other Injectionable Medications
  • 6.3.1 Pramlintide
  • 6.3.2 Exenatide
• 6.4 Market Share as per Classes in Type 2 Diabetes

7. NovoLog (insulin aspart)

• 7.1 Introduction
• 7.2 Mechanism of Action
• 7.3 Clinical Studies
  • 7.3.1 Subcutaneous NovoLog Administration in Type 2 Diabetes
  • 7.3.2 Pump Therapy in Type 2 Diabetes
• 7.4 Approval History of NovoLog
• 7.5 Factors Affecting Sales
  • 7.5.1 Growing Insulin Market
  • 7.5.2 Advantage of NovoLog over Regular Human Insulin and Other Insulin Analogs
  • 7.5.3 Prevention of Spiking Blood Sugar between Meals
  • 7.5.4 Effective treatment for Low blood sugar at night
  • 7.5.5 Very Low Competition at Launch Year
• 7.6 Drug Evaluation
  • 7.6.1 Drug Risk Benefit Score
  • 7.6.2 Intensity of Competition
• 7.7 Sales Estimates
  • 7.7.1 Target Patient Pool for NovoLog
  • 7.7.2 Dosing
  • 7.7.3 Market Penetration
  • 7.7.4 Annual Cost of Therapy
  • 7.7.5 Sales Projections of NovoLog

8. Diabetes Market: Appendix

• 8.1 Market Definitions
• 8.2 List of Abberiviations
• 8.3 Research Methodology
  • 8.3.1 Coverage
  • 8.3.2 Secondary Research
  • 8.3.3 Forecasting
  • 8.3.4 Number of patients approved to take the drug
  • 8.3.5 Net Penetration of Drug
  • 8.3.6 Net Annual Dosing
  • 8.3.7 Annual Cost of Therapy
• 8.4 Drug Sales Estimates Model
• 8.5 Contact Us
• 8.6 Disclaimer

9. Sources

• Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
• Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
• Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010
• Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010
• Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials
• Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
• Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
• Table 8: Diabetes Drugs Evolution
• Table 9: Subcutaneous Administration of NovoLog for Type 2 Diabetes
• Table 10: Pump Therapy in Type 2 Diabetes
• Table 11: Approval History of NovoLog
• Table 12: Drug Risk Benefit Score of NovoLog
• Table 13: NovoLog, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011
• Table 14: NovoLog, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2020
• Table 15: NovoLog, Type 2 Diabetes, the US, Sales Estimates ($m), 2002-2020
• Table 16: NovoLog, Type 2 Diabetes, the UK, Sales Estimates ($m), 2002-2020
• Table 17: NovoLog, Type 2 Diabetes, France, Sales Estimates ($m), 2002-2020
• Table 18: NovoLog, Type 2 Diabetes, Germany, Sales Estimates ($m), 2002-2020
• Table 19: NovoLog, Type 2 Diabetes, Italy, Sales Estimates ($m), 2002-2020
• Table 20: NovoLog, Type 2 Diabetes, Spain, Sales Estimates ($m), 2002-2020
• Table 21: NovoLog, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020

• Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010
• Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030
• Figure 3: Diabetes, World, Mortality, 2010
• Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
• Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020
• Figure 6: Mechanism of Action of Sulfonylureas
• Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
• Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
• Figure 9: Mechanism of Action of Thiazolidinediones
• Figure 10: Mechanism of Action of DPP IV Inhibitors
• Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010
• Figure 12: NovoLog, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2010
• Figure 13: NovoLog, Type 2 Diabetes, the US, Sales Estimates ($m), 2002-2020
• Figure 14: NovoLog, Type 2 Diabetes, the UK, Sales Estimates ($m), 2002-2020
• Figure 15: NovoLog, Type 2 Diabetes, France, Sales Estimates ($m), 2002-2020
• Figure 16: NovoLog, Type 2 Diabetes, Germany, Sales Estimates ($m), 2002-2020
• Figure 17: NovoLog, Type 2 Diabetes, Italy, Sales Estimates ($m), 2002-2020
• Figure 18: NovoLog, Type 2 Diabetes, Spain, Sales Estimates ($m), 2002-2020
• Figure 19: NovoLog, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020
• Figure 20: NovoLog, Diabetes, Global, Sales Distribution (%), 2020
• Figure 21: Patients Approved for the Drug

相關商品

糖尿病相關市場調查報告書

Glucagon-Like Peptide-1(GLP-1)受體激動劑:目標開發平台及相關利益者分析(2012年)
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
價格 : US $ 2600
出版日期 : 2012年03月

全球糖尿病治療藥物市場(到2017年為止):更好的血糖管理和潛在的低血糖風險的減輕與DPP-IV抑制劑和GLP-1作用藥的市場佔有率擴大相關
Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
價格 : US $ 3500
出版日期 : 2012年02月

第二型糖尿病:全球藥物預測和治療分析
Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020
價格 : US $ 6995
出版日期 : 2012年02月

GlobalData發行的製藥相關市場調查報告書

肺支氣管發育不良:全球臨床實驗檢討

Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

病毒性呼吸道感染疾病:全球臨床實驗檢討

Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

心搏過速 (快速心律不整):全球臨床實驗檢討

Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!